Author

Jean M. Mulcahy Levy

Morgan Adams FoundationORCID 0000-0002-3022-4246Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Emil Bratbak· 2 shared Nicholas K. ForemaniD· 2 shared Rajeev VibhakariD· 2 shared Shadi ZahediiD· 2 shared Abiola Abdulrahman AyanlajaiD· 1 shared Adam GreeniD· 1 shared Adam L. GreeniD· 1 shared Andrea M. GriesingeriD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Emil Bratbak

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Preclinical evaluation of ixazomib for high-risk pediatric brain tumors

Elizabeth Janko, Faye M. Walker, Mathew Slade, Etienne P. Danis, Pradeep Bompada, Lays Martin Sobral, Julia Chapman, Ishmeen Kaur, Simran Bal, Gabrielle Link, Nicholas McQuillan, Jean M. Mulcahy Levy, Adam L. Green, Nathan A. Dahl

This study evaluates ixazomib's efficacy against high-risk pediatric brain tumors, finding it cytotoxic but with limited CNS penetration.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology

Multi-pronged analysis of pediatric low-grade glioma reveals a unique tumor microenvironment associated with BRAF alterations

Shadi Zahedi, Kent A. Riemondy, Tian Liu, Andrea M. Griesinger, Andrew M. Donson, April Ann Apfelbaum, Rui Fu, Julian Grandvallet Contreras, Michele Crespo, John A. DeSisto, Madeline M. Groat, Emil Bratbak, Adam Green, Todd Cameron Hankinson, Michael H. Handler, , Jean M. Mulcahy Levy

This study uses multi-omics approaches to analyze pediatric low-grade glioma and identifies immune-related differences linked to BRAF mutations.

Brain Pathology · Jun 30, 2025Peer-reviewedCancer Biology

Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma

Abiola Abdulrahman Ayanlaja, Michael Chang, Kriti Lalwani, Maria Ioannou, Jiawan Wang, Shreya Jagtap, Yanbo Yang, Calixto‐Hope G. Lucas, Jean M. Mulcahy Levy, Robyn D. Gartrell, Christine A. Pratilas, Karisa C. Schreck

This study shows that combining SHP2 inhibition with BRAF inhibitors overcomes resistance in BRAF V600E-driven gliomas by suppressing RAS/ERK signaling and preventing tumor growth.

Neuro-Oncology Advances · Jan 1, 2025Peer-reviewedCancer Biology

The assessment of therapeutic autophagy inhibition in NF1 mutated tumor cells

Shadi Zahedi, Eliza Baird-Daniel, Kyle Brandon Williams, Rory L. Williams, Andrew Morin, Michelle Crespo, Emil Bratbak, Kendra Jones, Rajeev Vibhakar, Nicholas K. Foreman, David A. Largaespada, Jean M. Mulcahy Levy

This study shows that autophagy inhibition enhances MEK inhibitor effectiveness in NF1-mutated tumor cells, both in vitro and in a clinical trial.

bioRxiv · Nov 12, 2024 · PreprintCancer Biology